Rauvolfia verticillata-derived pectic polysaccharides alleviate ulcerative colitis via regulating macrophage polarization and inhibiting the JAK2/STAT3-NOS2 pathway

Abstract

Objective: To investigate the effect of pectic polysaccharides isolated from Rauvolfia verticillata on ulcerative colitis and its underlying mechanisms.

Methods: Pectic polysaccharides were characterized using high-performance liquid chromatography with 1-phenyl-3-methyl-5-pyrazolone pre-column derivatization, phenol-sulfuric acid assay, and gel permeation chromatography. HT-29 cells were stimulated with lipopolysaccharide and then treated with pectic polysaccharides; conditioned medium was applied to THP-1-derived macrophages to assess cell viability and polarization, while tight junction protein expression was analyzed in HT-29 cells. Furthermore, a mouse model of dextran sulfate sodium-induced colitis was treated with oral pectic polysaccharides or NOS2 overexpression. Body weight, disease activity index, colon length, histopathology, and the protein expression related to the JAK2/STAT3-NOS2 signaling were evaluated.

Results: The pectic polysaccharide was characterized as an acidic pectic polysaccharide, primarily composed of galacturonic acid and various neutral sugars, with a narrow molecular weight distribution and high purity. Pectic polysaccharides significantly enhanced THP-1 macrophage viability, promoted M1 to M2 polarization, and upregulated the expression of epithelial tight junction proteins. In addition, pectic polysaccharide treatment attenuated body weight loss, lowered disease activity index scores and improved colon histology in mice with dextran sulfate sodium-induced colitis. It also reduced JAK2/STAT3 phosphorylation and NOS2 expression, and increased the expression of tight junction proteins (ZO-1, occludin, and claudin-1).

Conclusions: Pectic polysaccharides attenuate ulcerative colitis by increasing M2-related macrophage markers, inhibiting the JAK2/ STAT3-NOS2 signaling, and enhancing epithelial barrier-related protein expression. These findings support pectic polysaccharides as a natural candidate for the treatment of ulcerative colitis.

Keywords

Rauvolfia-derived polysaccharides / Ulcerative colitis / Macrophage polarization / JAK2/STAT3-NOS2 signaling / Epithelial barrier

Conflict of interest statement

The authors declare that they have no conflict of interest.

Funding

This work was supported by the Key Research and Development Project of Hainan Province (ZDYF2022SHFZ099) and the Academic Enhancement Support Program of Hainan Medical University (XSTS2025040 and XSTS2025063).

Data availability statement

The data supporting the findings of this study are available from the corresponding authors upon request.

Authors’ contributions

FJ, NL, LM, and XPM conceptualized the study. FJ, NL, HDW, XPM, and LM contributed to the methodology and data collection. FJ, NL, HDW, and XPM contributed to data analysis. FJ and NL performed the cell experiments, while FJ, HDW, and XPM conducted the animal experiments. FJ, NL, HDW, XPM, and LM prepared the original draft, and reviewed and edited the manuscript. XPM and LM managed the project, and FJ and NL were responsible for visualization. All authors contributed to final approval of the version to be published.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci 2024; 45(10): 892-903.

[2] Nguyen L, Parra VV. Surgical management of ulcerative colitis. Surg Clin North Am 2025; 105(2): 289-299.

[3] Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative colitis: Molecular insights and intervention therapy. Mol Biomed 2024; 5(1). doi: 10.1186/s43556-024-00207-w.

[4] Wan J, Shen J, Zhong J, Ge W, Miao Y, Zhang X, et al. Natural course of ulcerative colitis in China: Differences from the West? United European Gastroenterol J 2024; 12(9): 1167-1178.

[5] Long D, Mao C, Zhang W, Zhu Y, Xu Y. Natural products for the treatment of ulcerative colitis: Focus on the JAK/STAT pathway. Front Immunol 2025; 16. doi: 10.3389/fimmu.2025.1538302.

[6] Kazemifard N, Golestani N, Jahankhani K, Farmani M, Ghavami SB. Ulcerative colitis: The healing power of macrophages. Tissue Barriers 2025; 13(2). doi: 10.1080/21688370.2024.2390218.

[7] Ohishi K, Dora D, Han CY, Guyer RA, Ohkura T, Kazimierczyk S, et al. Resolving resident colonic muscularis macrophage diversity and plasticity during colitis. Inflamm Bowel Dis 2025; 31(1): 151-168.

[8] Saurabh NK, Khan MM, Kirabo A. A future avenue of treatment ulcerative colitis targeting macrophage polarization: A phytochemical application. Crohns Colitis 360 2024; 6(4). doi: 10.1093/crocol/otae070.

[9] Goodarzi S, Abdolghaffari AH, Najafi B, Pirali Hamedani M, Tavakoli S, Marvi M, et al. Isoimperatorin alleviates acetic acid-induced colitis in rats. Asian Pac J Trop Biomed 2024; 14(4): 147-153.

[10] Guo Y, Li Y, Cao Q, Ye L, Wang J, Guo M. The function of natural polysaccharides in the treatment of ulcerative colitis. Front Pharmacol 2022; 13. doi: 10.3389/fphar.2022.927855.

[11] Lu H, Shen M, Chen Y, Yu Q, Chen T, Xie J. Alleviative effects of natural plant polysaccharides against DSS-induced ulcerative colitis via inhibiting inflammation and modulating gut microbiota. Food Res Int 2023; 167. doi: 10.1016/j.foodres.2023.112630.

[12] Dilixiati Y, Aipire A, Song M, Nijat D, Wubuli A, Cao Q, et al. The potential role of plant polysaccharides in treatment of ulcerative colitis. Pharmaceutics 2024; 16(8). doi: 10.3390/pharmaceutics16081073.

[13] Wang N, Xie YW, Li MY, Li FF, Zhang LY, You YL, et al. Simultaneous determination of five alkaloids from Rauvolfia vomitoria in rat plasma by LC-MS/MS: Application to a comparative pharmacokinetic study in normal and type 2 diabetic rats. J Sep Sci 2021; 44(7): 1391-1403.

[14] Neupane A, Jnawali B, Ghimire SK. Anthropogenic disturbances and invasion of Mikania micrantha threaten Rauvolfia serpentina populations in Nepal. Ecol Evol 2025; 15(12). doi: 10.1002/ece3.72731.

[15] Kumar S, Kumari D, Singh B. Genus Rauvolfia: A review of its ethnopharmacology, phytochemistry, quality control/quality assurance, pharmacological activities and clinical evidence. J Ethnopharmacol 2022; 295. doi:10.1016/j.jep.2022.115327.

[16] Anigboro AA, Avwioroko OJ, Oborirhovo O, Akeghware O, Durugbo EU, Apiamu A, et al. Characterization, anti-glycation, anti-inflammation, and lipase inhibitory properties of Rauvolfia vomitoria leaf extract: In vitro and in silico evaluations for obesity treatment. Appl Biochem Biotechnol 2024; 196(10): 6864-6892.

[17] Pereira De Araújo M, Sato MO, Sato M, Bandara Wm KM, Coelho LFL, Souza RLM, et al. Unbalanced relationships: Insights into the interaction between gut microbiota, geohelminths, and schistosomiasis. PeerJ 2022; 10. doi: 10.7717/peerj.13401.

[18] Schemczssen-Graeff Z, Silva CR, De Freitas PNN, Constantin PP, Pileggi SAV, Olchanheski LR, et al. Probiotics as a strategy for addressing helminth infections in low-income countries: Working smarter rather than richer. Biochem Pharmacol 2024; 226. doi: 10.1016/j.bcp.2024.116363.

[19] Miao XP, Sun XN, Li QS, Cui LJ, Wang XY, Zhuang GF, et al. Pectic polysaccharides extracted from Rauvolfia verticillata (Lour.) Baill. var. hainanensis Tsiang ameliorate ulcerative colitis via regulating the MAPKs and NF-κB pathways in dendritic cells. Clin Exp Pharmacol Physiol 2019; 46(1): 48-55.

[20] Guo YF, Wang Y, Wu H, Wang L, Miao X. Rauvolfia verticillata pectic polysaccharides alleviate inflammation-associated colorectal cancer and correlate with modulation of gut microbiota, short-chain fatty acid metabolism, and NF-κB/IL-6/STAT3 signaling pathways. Nutr Cancer 2025; 77(10): 1183-1199.

[21] Wu H, Jiang F, Yuan W, Zhao Y, Liu N, Miao X. Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway. PLoS One 2024; 19(4). doi: 10.1371/journal.pone.0301660.

[22] Subramanyam SH, Hriczko JT, Pappas A, Schippers A, Wagner N, Ohl K, et al. Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity. Sci Rep 2023; 13(1): 3762. doi: 10.1038/s41598-023-30616-w.

[23] Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69(2): 238-249.

[24] Gupta M, Mishra V, Gulati M, Kapoor B, Kaur A, Gupta R, et al. Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology 2022; 30(2): 397-434.

[25] Wu ZW, Liu XC, Quan CX, Tao XY, Yi L, Zhao XF, et al. Novel galactose-rich polysaccharide from Ganoderma lucidum: Structural characterization and immunomodulatory activities. Carbohydr Polym 2025; 362. doi: 10.1016/j.carbpol.2025.123695.

[26] Cruz-Rubio JM, Riva A, Cybulska J, Zdunek A, Berry D, Loeppert R, et al. Neutral and pectic heteropolysaccharides isolated from Opuntia joconostle mucilage: Composition, molecular dimensions and prebiotic potential. Int J Mol Sci 2023; 24(4). doi: 10.3390/ijms24043208.

[27] Wu J, Li C, Bai L, Wu J, Bo R, Ye M, et al. Structural differences of polysaccharides from Astragalus before and after honey processing and their effects on colitis mice. Int J Biol Macromol 2021; 182: 815-824.

[28] Basu A, Weiss RJ. Glycosaminoglycan analysis: Purification, structural profiling, and GAG-protein interactions. Methods Mol Biol 2023; 2597: 159-176.

[29] Black I, Heiss C, Carlson RW, Azadi P. Linkage analysis of oligosaccharides and polysaccharides: A tutorial. Methods Mol Biol 2021; 2271: 249-271.

[30] Zheng Z, Pan X, Xu J, Wu Z, Zhang Y, Wang K. Advances in tracking of polysaccharides in vivo: Labeling strategies, potential factors and applications based on pharmacokinetic characteristics. Int J Biol Macromol 2020; 163: 1403-1420.

[31] Chen L, Zhao S, Chen Q, Luo P, Li X, Song Y, et al. Poria cocos polysaccharides ameliorate AOM/DSS-induced colorectal cancer in mice by remodeling intestinal microbiota composition and enhancing intestinal barrier function. Int J Biol Macromol 2025; 315(Pt 2). doi: 10.1016/j.ijbiomac.2025.144477.

[32] Shi JY, Wang YJ, Bao QW, Qin YM, Li PP, Wu QQ, et al. Polygonatum cyrtonema Hua polysaccharide alleviates ulcerative colitis via gut microbiota-independent modulation of inflammatory immune response. Carbohydr Polym 2025; 356. doi: 10.1016/j.carbpol.2025.123387.

[33] Huo DY, Li YF, Song LJ, Zhang WX, Li XD, Zhang J, et al. Colon-targeted Ginseng polysaccharides-based microspheres for improving ulcerative colitis via anti-inflammation and gut microbiota modulation. Adv Healthc Mater 2025; 14(6). doi: 10.1002/adhm.202404122.

[34] Zhao T, Zhang Y, Nan L, Zhu Q, Wang S, Xie Y, et al. Impact of structurally diverse polysaccharides on colonic mucin O-glycosylation and gut microbiota. NPJ Biofilms Microbiomes 2023; 9(1): 97. doi: 10.1038/s41522-023-00468-3.

[35] Tao Q, Liang Q, Fu Y, Qian J, Xu J, Zhu Y, et al. Puerarin ameliorates colitis by direct suppression of macrophage M1 polarization in DSS mice. Phytomedicine 2024; 135. doi: 10.1016/j.phymed.2024.156048.

[36] Zhao H, Zhou Y, Xu J, Zhang Y, Wang H, Zhao C, et al. Short-chain fatty acid-producing bacterial strains attenuate experimental ulcerative colitis by promoting M2 macrophage polarization via JAK/STAT3/FOXO 3 axis inactivation. J Transl Med 2024; 22(1): 369. doi: 10.1186/s12967-024-05122-w.

[37] Tang H, Li Q, Zha Z, Jiao Y, Yang B, Cheng Z, et al. Xylan acetate ester ameliorates ulcerative colitis through intestinal barrier repair and inflammation inhibition via regulation of macrophage M1 polarization. Int J Biol Macromol 2024; 280(Pt 1). doi: 10.1016/j.ijbiomac.2024.135551.

[38] Lv W, Jin W, Lin J, Wang Z, Ma Y, Zhang W, et al. Forsythia suspensa polyphenols regulate macrophage M1 polarization to alleviate intestinal inflammation in mice. Phytomedicine 2024; 125. doi: 10.1016/j.phymed.2024.155336.

[39] Calviño-Suárez C, Durán-Rubí M, Brea J, Moreira D, Ardao I, Brocos-Mosquera I, et al. Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response. Front Immunol 2025; 16. doi: 10.3389/fimmu.2025.1609740.

[40] Van Gennep S, Fung ICN, Jong DC, Ramkisoen RK, Clasquin E, De Jong J, et al. Histological outcomes and JAK-STAT signalling in ulcerative colitis patients treated with tofacitinib. J Crohns Colitis 2024; 18(8): 1283-1291.

[41] Spalinger MR, Sayoc-Becerra A, Ordookhanian C, Canale V, Santos AN, King SJ, et al. The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions. J Crohns Colitis 2021; 15(3): 471-484.

[42] Bjorner K, Chen WN, Gannavarapu VR, Axling F, Gulyas M, Halim MA, et al. High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival. Ups J Med Sci 2023; 28. doi: 10.48101/ujms.v128.10241.

[43] Drieu La Rochelle J, Ward J, Stenke E, Yin Y, Matsumoto M, Jennings R, et al. Dysregulated NOX1-NOS2 activity as hallmark of ileitis in mice. Mucosal Immunol 2024; 17(6): 1326-1336.

[44] Kim HY, Jeon H, Bae CH, Lee Y, Kim H, Kim S. Rumex japonicus Houtt. alleviates dextran sulfate sodium-induced colitis by protecting tight junctions in mice. Integr Med Res 2020; 9(2). doi: 10.1016/j.imr.2020.02.006.

[45] Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288(6): G1328-G1338. doi: 10.1152/ajpgi.00467.2004.